Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations

In a Phase II trial a combination targeted therapy achieved a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.